Cargando…

Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation

Siponimod (Mayzent(®)), a sphingosine 1-phosphate receptor (S1PR) modulator which prevents lymphocyte egress from lymphoid tissues, is approved for the treatment of relapsing-remitting and active secondary progressive multiple sclerosis. It can cross the blood–brain barrier (BBB) and selectively bin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gruchot, Joel, Lein, Ferdinand, Lewen, Isabel, Reiche, Laura, Weyers, Vivien, Petzsch, Patrick, Göttle, Peter, Köhrer, Karl, Hartung, Hans-Peter, Küry, Patrick, Kremer, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655930/ https://www.ncbi.nlm.nih.gov/pubmed/36362063 http://dx.doi.org/10.3390/ijms232113278

Ejemplares similares

The Molecular Basis for Remyelination Failure in Multiple Sclerosis
por: Gruchot, Joel, et al.
Publicado: (2019)

Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
por: Dietrich, Michael, et al.
Publicado: (2022)

An unmet clinical need: roads to remyelination in MS
por: Göttle, Peter, et al.
Publicado: (2019)

Teriflunomide promotes oligodendroglial differentiation and myelination
por: Göttle, Peter, et al.
Publicado: (2018)

Myelin repair is fostered by the corticosteroid medrysone specifically acting on astroglial subpopulations
por: Silva Oliveira Junior, Markley, et al.
Publicado: (2022)

Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
por: Reiche, Laura, et al.
Publicado: (2019)

Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence
por: Manousi, Anastasia, et al.
Publicado: (2021)

Teriflunomide as a therapeutic means for myelin repair
por: Göttle, Peter, et al.
Publicado: (2023)

Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses
por: Gruchot, Joel, et al.
Publicado: (2019)

Human endogenous retroviruses: ammunition for myeloid cells in neurodegenerative diseases?
por: Gruchot, Joel, et al.
Publicado: (2019)

Neurological manifestations of severe acute respiratory syndrome coronavirus 2—a controversy ‘gone viral’
por: Förster, Moritz, et al.
Publicado: (2020)

Transgenic expression of the HERV-W envelope protein leads to polarized glial cell populations and a neurodegenerative environment
por: Gruchot, Joel, et al.
Publicado: (2023)

Drug repurposing for neuroregeneration in multiple sclerosis
por: Küry, Patrick, et al.
Publicado: (2018)

A Novel Ex Vivo Model to Study Therapeutic Treatments for Myelin Repair following Ischemic Damage
por: Werner, Luisa, et al.
Publicado: (2023)

CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation
por: Kremer, David, et al.
Publicado: (2016)

Intracellular Protein Shuttling: A Mechanism Relevant for Myelin Repair in Multiple Sclerosis?
por: Göttle, Peter, et al.
Publicado: (2015)

TLR4 Associated Signaling Disrupters as a New Means to Overcome HERV-W Envelope-Mediated Myelination Deficits
por: Göttle, Peter, et al.
Publicado: (2021)

Multiple sclerosis drug repurposing for neuroregeneration
por: Göttle, Peter, et al.
Publicado: (2023)

Mesenchymal Stem Cell Conditioning Promotes Rat Oligodendroglial Cell Maturation
por: Jadasz, Janusz Joachim, et al.
Publicado: (2013)

Siponimod for multiple sclerosis
Publicado: (2021)

Insulin-Like Growth Factor 1 Attenuates the Pro-Inflammatory Phenotype of Neutrophils in Myocardial Infarction
por: Nederlof, Rianne, et al.
Publicado: (2022)

C21orf91 Regulates Oligodendroglial Precursor Cell Fate—A Switch in the Glial Lineage?
por: Reiche, Laura, et al.
Publicado: (2021)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

The transcription factor reservoir and chromatin landscape in activated plasmacytoid dendritic cells
por: Mann-Nüttel, Ritu, et al.
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Does Siponimod Exert Direct Effects in the Central Nervous System?
por: Kipp, Markus
Publicado: (2020)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells
por: Frerichs, Lucie M., et al.
Publicado: (2023)

Cryptococcal meningoencephalitis in an IgG(2)-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report
por: Wienemann, Tobias, et al.
Publicado: (2020)

Effect of Siponimod on Brain and Spinal Cord Imaging Markers of Neurodegeneration in the Theiler’s Murine Encephalomyelitis Virus Model of Demyelination
por: Pol, Suyog, et al.
Publicado: (2023)

Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights
por: Müller, Melanie R., et al.
Publicado: (2022)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

Impact of siponimod on vaccination response in a randomized, placebo-controlled study
por: Ufer, Mike, et al.
Publicado: (2017)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eq7cpto2tiksv0rog2a4i8os2c